Neoadjuvant chemotherapy is associated with a high rate of perioperative blood transfusion at the time of interval cytoreductive surgery.
Kevin W McCoolEmmanuel SampeneBrock PolnaszekJoseph ConnorErin E MedlinLisa M BarroilhetPublished in: BMC cancer (2018)
Women undergoing neoadjuvant chemotherapy for ovarian cancer are at high risk of exposure to blood transfusion at the time of interval cytoreductive surgery. Future studies will continue to evaluate the safety and impact of transfusion on ovarian cancer survival in this at risk population.
Keyphrases
- neoadjuvant chemotherapy
- minimally invasive
- locally advanced
- coronary artery bypass
- lymph node
- sentinel lymph node
- cardiac surgery
- surgical site infection
- polycystic ovary syndrome
- squamous cell carcinoma
- patients undergoing
- metastatic renal cell carcinoma
- percutaneous coronary intervention
- acute kidney injury
- acute coronary syndrome
- adipose tissue
- case control
- free survival
- insulin resistance
- cervical cancer screening